Literature DB >> 20527230

Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer.

G K Siddiqui1, K Elmasry, A C Wong Te Fong, C Perrett, R Morris, J C C Crow, A B Maclean.   

Abstract

OBJECTIVES: The aim of this study was to examine the prognostic significance of vascular endothelial growth factor (VEGF) in epithelial ovarian cancer (EOC).
METHODS: Surgical specimens of 105 patients with primary EOC FIGO Stages 1 to 4, who underwent surgical staging, were investigated. Expression of VEGF was evaluated by immunohistochemical staining using related monoclonal antibodies. The correlation of this data with survival and established prognostic factors such as histological grade, FIGO stage and residual tumour status was evaluated. Multivariate analysis and correlation tests were performed.
RESULTS: The results of VEGF expression were correlated with clinicopathological variables and overall survival. No correlation between the VEGF expression and clinicopathological factors was identified. However, VEGF expression was found to be significantly correlated to survival, and a prognostic factor independent of the stage of disease and residual tumour status (p < 0.0001).
CONCLUSION: High intratumoral VEGF expression, a marker of angiogenesis, appeared to be an independent prognostic factor for overall survival in women with EOC. Angiogenic evaluation of patients with EOC may play a role in predicting a subgroup of patients with aggressive disease. These patients could be the target of front-line molecular targeted therapy with anti-angiogenic agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20527230

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  10 in total

1.  Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Bradley J Monk; Joan L Walker; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Gini F Fleming; Peter C Lim; Stephen C Rubin; Noriyuki Katsumata; Sharon X Liang
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

Review 2.  First-line and maintenance therapy for ovarian cancer: current status and future directions.

Authors:  Antonio González-Martín; Luisa Sánchez-Lorenzo; Raquel Bratos; Raúl Márquez; Luis Chiva
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival.

Authors:  Bente Vilming Elgaaen; Ole Kristoffer Olstad; Leiv Sandvik; Elin Odegaard; Torill Sauer; Anne Cathrine Staff; Kaare M Gautvik
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

4.  Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia.

Authors:  R Agarwal; V Harding; D Short; R A Fisher; N J Sebire; R Harvey; D Patel; P M Savage; A K P Lim; M J Seckl
Journal:  Br J Cancer       Date:  2012-02-28       Impact factor: 7.640

Review 5.  Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.

Authors:  Samar Masoumi Moghaddam; Afshin Amini; David L Morris; Mohammad H Pourgholami
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

Review 6.  Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis.

Authors:  Juan Li; Yongjian Ju
Journal:  Iran J Med Sci       Date:  2015-01

7.  Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?

Authors:  Inga Bekes; Thomas W P Friedl; Tanja Köhler; Volker Möbus; Wolfgang Janni; Achim Wöckel; Christine Wulff
Journal:  Mol Cancer       Date:  2016-02-12       Impact factor: 27.401

8.  Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance.

Authors:  Reza Ranjbar; Foroogh Nejatollahi; Ahmad Sina Nedaei Ahmadi; Hossein Hafezi; Akbar Safaie
Journal:  Iran J Cancer Prev       Date:  2015-08-24

9.  Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.

Authors:  Samar Masoumi-Moghaddam; Afshin Amini; Ai-Qun Wei; Gregory Robertson; David L Morris
Journal:  Oncotarget       Date:  2015-09-29

10.  The role of a drug-loaded poly (lactic co-glycolic acid) (PLGA) copolymer stent in the treatment of ovarian cancer.

Authors:  Yanqing Wang; Xiaoyin Qiao; Xiao Yang; Mengqin Yuan; Shu Xian; Li Zhang; Dongyong Yang; Shiyi Liu; Fangfang Dai; Zhikai Tan; Yanxiang Cheng
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.